Market Place
Sourcing Support
Report from the General Meeting of Promore Pharma AB Held on 29 December 2023
29 Dec 2023 //
ACCESSWIRE
Promore has received approval for continued trading on Nasdaq
21 Dec 2023 //
ACCESSWIRE
Update on Reverse Acquisition - PMD Completes Private Placement
08 Dec 2023 //
ACCESSWIRE
Promore Pharma initiates voluntary liquidation
12 Oct 2023 //
ACCESSWIRE
Report from the General Meeting of Promore Pharma AB held on 5 October 2023
05 Oct 2023 //
ACCESSWIRE
Promore Pharma Engages Erik Penser Bank as Liquidity Provider
16 Aug 2023 //
ACCESSWIRE
Report from the Annual General Meeting of Promore Pharma AB held on 27 June 2023
27 Jun 2023 //
ACCESSWIRE
Promore Pharma Reduces Costs & Explores the Conditions for a Reverse Acquisition
22 Jun 2023 //
ACCESSWIRE
Promore Pharma’s AGM related Documents Published
25 May 2023 //
ACCESSWIRE
Interim Report January - March 2023
23 May 2023 //
ACCESSWIRE
Promore Pharma’s Annual Report 2022
09 May 2023 //
ACCESSWIRE
Promore Pharma Reports Outcome from Clinical Phase II Study with Ensereptide
20 Apr 2023 //
ACCESSWIRE
Promore`s phase 2 scar trial fail sends stock spiraling down
20 Apr 2023 //
FIERCE BIOTECH
Promore Reaches the Clean File Milestone in its Phase II Trial with Ensereptide
27 Feb 2023 //
ACCESSWIRE
Invitation regarding Promore Pharma`s Report for the Fourth Quarter 2022
27 Feb 2023 //
ACCESSWIRE
Invitation to Conference Regarding Promore’s Interim Report for Q3 2022
24 Nov 2022 //
ACCESSWIRE
Promore Pharma Provides an Update on the Phase II Trial with Ensereptide
01 Nov 2022 //
ACCESSWIRE
Promore Pharma Granted EU Patent Regarding Treatment of Chronic Wounds
10 Aug 2022 //
ACCESSWIRE
The Last Clinic Visit Conducted in Promore Pharma`s PII Study of Ensereptide
13 Jun 2022 //
ACCESSWIRE
Invitation to Conference Call Regarding Promore Pharma’s Interim Report
13 May 2022 //
ACCESSWIRE
Promore Pharma`s Annual Report 2021 and AGM related Documents Published
26 Apr 2022 //
ACCESSWIRE
Notice of Annual General Meeting Promore Pharma AB (publ)
12 Apr 2022 //
ACCESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.